Cellenkos, Inc.
Cellenkos, Inc.
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD) | graft versus host disease, immune system disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-05-11 | NCT07576699 | |
| CK0801 for Treatment of Aplastic Anemia | Bone Marrow Failure Disorders, Hemic and Lymphatic Diseases, anemia, aplastic anemia, bone marrow disorder, hematologic disorder | Not yet recruiting | Phase 2 | 2026-04-03 | NCT07499102 | |
| Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, blood platelet disease, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm, primary myelofibrosis, thrombocytosis disease | Recruiting | Phase 1 | 2025-04-13 | NCT05423691 | |
| A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF) | Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder | Active, not recruiting | Phase 1 | 2025-04-13 | NCT03773393 | |
| Regulatory T Cells for Amyotrophic Lateral Sclerosis | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Active, not recruiting | Phase 1 | 2025-04-11 | NCT05695521 |